Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APD-209 for acute adenoviral epidemic keratoconjunctivitis
2012-005694-31Phase 2Completed
- Sponsor
- Adenovir Pharma
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in adenoviral keratoconjunctivitis (EKC) comparing APD-209 eye drops with Placebo eye drops (2 arms). Primary endpoint: Virological success at days 3 to 14. Started May 2013; status: completed.
02
Drugs
APD-209
03
Conditions
adenoviral keratoconjunctivitis (EKC)
Beyond the preview
Go deeper on 2012-005694-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005694-31.